Long-term follow-up study of fianlimab and cemiplimab combination treatment in adult patients with melanoma

2 1 1 1

What is this study about?

This study focuses on patients with melanoma, a type of skin cancer, who previously participated in a treatment program using two medications: fianlimab and cemiplimab. Both medications are given through intravenous administration (delivered directly into a vein). The purpose is to monitor the long-term health outcomes of patients who received this combination treatment.

The study will track patients who previously received treatment with LIBTAYO (also known as cemiplimab) and fianlimab (also known as REGN3767). These medications belong to a group of biological or biotechnology-derived treatments. The medications work together to help the body’s immune system fight against melanoma cells.

During this extended follow-up study, researchers will monitor patients’ overall survival and track how their disease responds to treatment over time. The study will also collect information about any health issues that may occur and any additional cancer treatments that patients receive after their initial treatment. This long-term monitoring will help understand how patients respond to the treatment combination over an extended period.

1 Initial treatment phase

You will receive two medications through intravenous infusion (delivered directly into your vein):

– Cemiplimab (LIBTAYO) 350 mg as a concentrate solution for infusion

– Fianlimab as an injection solution

2 Monitoring period

Your health status will be regularly monitored to assess:

– How your melanoma (skin cancer) responds to treatment

– Whether the cancer has stopped growing or spreading (disease control)

– How long the treatment benefits last (duration of response)

Any side effects or health changes will be documented during this period

3 Follow-up assessments

Regular medical evaluations will track:

– Your overall survival progress

– Whether the cancer has progressed

– Any serious health issues that may occur

– Any additional cancer treatments you receive after completing the initial treatment

4 Long-term observation

The study continues until October 2029

Your health status will be monitored throughout this period to understand the long-term effects of the treatment

Who Can Join the Study?

Must be diagnosed with melanoma (a type of skin cancer)
Must have previously participated in study R3767-ONC-1613 specifically in cohorts 6, 15, or 16
Must be an adult (18 years or older)
Both men and women can participate
Must be able to understand and sign an informed consent form
Must be willing to participate in follow-up visits and assessments as required by the study
Must be able to comply with all study procedures and requirements
Must be willing to have their Overall Survival (OS) (length of time from start of treatment that patient is still alive) assessed during the study

Who Cannot Join the Study?

History of autoimmune disease (conditions where the body’s immune system attacks healthy cells)
Active or untreated brain metastases (cancer that has spread to the brain)
Previous treatment with any immunotherapy (treatments that help your immune system fight cancer)
Uncontrolled high blood pressure or heart disease
Active infection requiring systemic treatment (medication that affects the whole body)
Pregnant or breastfeeding women
Known allergy or sensitivity to study medications
Any other active cancer in the past 2 years (except for adequately treated non-melanoma skin cancer)
Serious medical conditions that could interfere with study participation
Immunosuppressive medication use (drugs that weaken the immune system)
History of organ transplant
Active hepatitis B or C (liver infections) or HIV infection

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Sv Vhhnurhqdmjhncr Udpfozjkkh Huuzadmv	Dublin	Ireland

Trial status

Country	Status	Recruitment Start
Ireland	Not yet recruiting	10.04.2025

Trial locations

Investigated drugs:

Fianlimab is a type of immunotherapy medication that helps the body’s immune system fight against cancer cells. It works by targeting specific proteins that cancer cells use to evade the immune system’s natural defenses.

Cemiplimab is also an immunotherapy medication that helps activate the immune system to fight cancer cells. It belongs to a class of drugs called PD-1 inhibitors, which work by blocking certain proteins that prevent the immune system from attacking cancer cells. When used together with Fianlimab, it may provide a more effective treatment approach for melanoma patients.

Investigated diseases:

Malignant melanoma

Melanoma – A type of skin cancer that develops from melanocytes, the cells that produce melanin (skin pigment). The disease typically begins in a mole or appears as a new dark spot on the skin. Melanoma can develop on any part of the body, including areas not regularly exposed to sunlight. As the disease progresses, the affected area may change in size, shape, or color. The cancer can spread to other parts of the body through the lymphatic system or bloodstream. Early changes often include asymmetry in moles, irregular borders, color variations, or increasing diameter.

Trial ID:

2024-517729-20-00

Protocol code:

R3767-ONC-2466

NCT ID:

NCT06848088

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Long-term follow-up study of fianlimab and cemiplimab combination treatment in adult patients with melanoma

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?